These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 37665501)

  • 1. Effectiveness of Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Prevention of Migraine: A Systematic Review and Meta-Analysis of Observational Cohort Studies.
    Ferreira VL; Mainka FF; Wiens A; Pontarolo R
    Clin Drug Investig; 2023 Sep; 43(9):669-680. PubMed ID: 37665501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention.
    Sacco S; Bendtsen L; Ashina M; Reuter U; Terwindt G; Mitsikostas DD; Martelletti P
    J Headache Pain; 2019 Jan; 20(1):6. PubMed ID: 30651064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Safety and Efficacy of Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibodies for the Preventive Treatment of Migraine: A Protocol for Multiple-Treatment Systematic Review and Meta-Analysis.
    Fernández-Bravo-Rodrigo J; Pascual-Morena C; Flor-García A; Saz-Lara A; Sequí-Dominguez I; Álvarez-Bueno C; Barreda-Hernández D; Cavero-Redondo I
    Int J Environ Res Public Health; 2022 Feb; 19(3):. PubMed ID: 35162776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness and Tolerability of the Pharmacology of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide and Its Receptor for the Prevention of Chronic Migraine: a Network Meta-analysis of Randomized Controlled Trials.
    Yang CP; Zeng BY; Chang CM; Shih PH; Yang CC; Tseng PT; Wang SJ
    Neurotherapeutics; 2021 Oct; 18(4):2639-2650. PubMed ID: 34580838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis.
    Zhu Y; Liu Y; Zhao J; Han Q; Liu L; Shen X
    Neurol Sci; 2018 Dec; 39(12):2097-2106. PubMed ID: 30182284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
    Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Gine-Cipres E; Pozo-Rosich P
    J Neurol; 2021 Oct; 268(10):3789-3798. PubMed ID: 33772636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials.
    Xu D; Chen D; Zhu LN; Tan G; Wang HJ; Zhang Y; Liu L
    Cephalalgia; 2019 Aug; 39(9):1164-1179. PubMed ID: 30789292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction in the severity and duration of headache following fremanezumab treatment in patients with episodic and chronic migraine.
    Ashina M; Cohen JM; Gandhi SK; Du E
    Headache; 2021 Jun; 61(6):916-926. PubMed ID: 34115380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison.
    Briceño-Casado MDP; Gil-Sierra MD; Fénix-Caballero S
    Farm Hosp; 2020 Aug; 44(5):212-217. PubMed ID: 32853126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.
    Viudez-Martínez A; Pascual-Carrasco A; Beltrán-Blasco I; Hernandez-Lorido R; F Ruiz de Apodaca R
    J Clin Pharm Ther; 2022 Jun; 47(6):814-823. PubMed ID: 35212025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Efficacy and Safety of Five Anti-calcitonin Gene-related Peptide Agents for Migraine Prevention: A Network Meta-analysis.
    Sun W; Cheng H; Xia B; Liu X; Li Y; Wang X; Liu C
    Clin J Pain; 2023 Oct; 39(10):560-569. PubMed ID: 37278480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials.
    Haghdoost F; Puledda F; Garcia-Azorin D; Huessler EM; Messina R; Pozo-Rosich P
    Cephalalgia; 2023 Apr; 43(4):3331024231159366. PubMed ID: 36855951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?
    Nagaraj K; Vandenbussche N; Goadsby PJ
    Neurol India; 2021; 69(Supplement):S59-S66. PubMed ID: 34003149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
    Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials.
    Masoud AT; Hasan MT; Sayed A; Edward HN; Amer AM; Naga AE; Elfil M; Alghamdi BS; Perveen A; Ashraf GM; Bahbah EI
    J Neurol Sci; 2021 Aug; 427():117505. PubMed ID: 34082147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of anti-CGRP monoclonal antibodies on central symptoms of migraine.
    Iannone LF; De Cesaris F; Ferrari A; Benemei S; Fattori D; Chiarugi A
    Cephalalgia; 2022 Nov; 42(13):1323-1330. PubMed ID: 35775208
    [TBL] [Abstract][Full Text] [Related]  

  • 20. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update.
    Sacco S; Amin FM; Ashina M; Bendtsen L; Deligianni CI; Gil-Gouveia R; Katsarava Z; MaassenVanDenBrink A; Martelletti P; Mitsikostas DD; Ornello R; Reuter U; Sanchez-Del-Rio M; Sinclair AJ; Terwindt G; Uluduz D; Versijpt J; Lampl C
    J Headache Pain; 2022 Jun; 23(1):67. PubMed ID: 35690723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.